Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Covidien neurology, autoimmune news

Covidien completed the spin-off of its pharmaceuticals business - its Mallinckrodt plc subsidiary - into a separate public company.

Read the full 198 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE